Abstract
Hepatitis C is a viral infection of the liver that results in acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. An estimated 170 million persons are chronically infected worldwide. The Hepatitis C virus is the pathogen agent responsible for hepatitis C. HCV is an enveloped RNA-positive virus of the flaviviridae family. The HCV genome shows remarkable sequence variability. This variability leads to the classification of HCV into 6 genotypes, numerous subtypes and HCV exists in each infected patient as quasi-species. The genotype may be linked to the severity of the disease and to the efficiency of the combination treatment with interferon and ribavirin. To date, no vaccine to prevent or cure HCV exists. Numerous HCV specific inhibitors have been designed and some are currently under clinical trials. However, resistances of HCV against these inhibitors have been identified. We developed the European Hepatitis C Virus Database (euHCVdb, http://euhcvdb.ibcp.fr/), a collection of functionally and structurally (3D-models) annotated HCV sequences integrated with sequence and structure analysis tools. We show below how the euHCVdb database is a useful in silico tool that can help drug design, combating resistance to drug treatment and understand structural biology of the HCV.
Keywords: Hepatitis C Virus, drug design, molecular modelling, database, resistance, virus, sequence analysis, structure analysis
Infectious Disorders - Drug Targets
Title: The euHCVdb Suite of In Silico Tools for Investigating the Structural Impact of Mutations in Hepatitis C Virus Proteins
Volume: 9 Issue: 3
Author(s): c. Combet, E. Bettler, R. Terreux, N. Garnier and G. Deleage
Affiliation:
Keywords: Hepatitis C Virus, drug design, molecular modelling, database, resistance, virus, sequence analysis, structure analysis
Abstract: Hepatitis C is a viral infection of the liver that results in acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. An estimated 170 million persons are chronically infected worldwide. The Hepatitis C virus is the pathogen agent responsible for hepatitis C. HCV is an enveloped RNA-positive virus of the flaviviridae family. The HCV genome shows remarkable sequence variability. This variability leads to the classification of HCV into 6 genotypes, numerous subtypes and HCV exists in each infected patient as quasi-species. The genotype may be linked to the severity of the disease and to the efficiency of the combination treatment with interferon and ribavirin. To date, no vaccine to prevent or cure HCV exists. Numerous HCV specific inhibitors have been designed and some are currently under clinical trials. However, resistances of HCV against these inhibitors have been identified. We developed the European Hepatitis C Virus Database (euHCVdb, http://euhcvdb.ibcp.fr/), a collection of functionally and structurally (3D-models) annotated HCV sequences integrated with sequence and structure analysis tools. We show below how the euHCVdb database is a useful in silico tool that can help drug design, combating resistance to drug treatment and understand structural biology of the HCV.
Export Options
About this article
Cite this article as:
Combet c., Bettler E., Terreux R., Garnier N. and Deleage G., The euHCVdb Suite of In Silico Tools for Investigating the Structural Impact of Mutations in Hepatitis C Virus Proteins, Infectious Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/1871526510909030272
DOI https://dx.doi.org/10.2174/1871526510909030272 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry The Supremacy of Synergism: A Comparison of Anticancer Activity of Rhizome Extract of Bistorta Amplexicaulis and Gallic Acid in Cancer Cell Lines and Primary Cells
Current Nutraceuticals Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
Current Pharmaceutical Design The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Surface Binding of Toxins and Heavy Metals by Probiotics
Mini-Reviews in Medicinal Chemistry Editorial: Advances in Epithelial Ovarian Cancer Therapy
Current Pharmaceutical Design Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery In-silico & In-vitro Identification of Structure-Activity Relationship Pattern of Serpentine & Gallic Acid Targeting PI3Kγ as Potential Anticancer Target
Current Cancer Drug Targets Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry